Cargando…

Nuclear-Targeted Deleted in Liver Cancer 1 (DLC1) Is Less Efficient in Exerting Its Tumor Suppressive Activity Both In Vitro and In Vivo

BACKGROUND: Deleted in liver cancer 1 (DLC1) serves as an important RhoGTPase activating protein (RhoGAP) protein that terminates active RhoA signaling in human cancers. Increasing evidence has demonstrated that the tumor suppressive activity of DLC1 depends not only on RhoGAP activity, but also rel...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Lo-Kong, Ko, Frankie Chi Fat, Sze, Karen Man-Fong, Ng, Irene Oi-Lin, Yam, Judy Wai Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180446/
https://www.ncbi.nlm.nih.gov/pubmed/21966542
http://dx.doi.org/10.1371/journal.pone.0025547
_version_ 1782212638532435968
author Chan, Lo-Kong
Ko, Frankie Chi Fat
Sze, Karen Man-Fong
Ng, Irene Oi-Lin
Yam, Judy Wai Ping
author_facet Chan, Lo-Kong
Ko, Frankie Chi Fat
Sze, Karen Man-Fong
Ng, Irene Oi-Lin
Yam, Judy Wai Ping
author_sort Chan, Lo-Kong
collection PubMed
description BACKGROUND: Deleted in liver cancer 1 (DLC1) serves as an important RhoGTPase activating protein (RhoGAP) protein that terminates active RhoA signaling in human cancers. Increasing evidence has demonstrated that the tumor suppressive activity of DLC1 depends not only on RhoGAP activity, but also relies on proper focal adhesion localization through its interaction with tensin family proteins. Recently, there are reports showing that DLC1 can also be found in the nucleus; however, the existence and the relative tumor suppressive activity of nuclear DLC1 have never been clearly addressed. METHODOLOGY AND PRINCIPAL FINDINGS: We herein provide new evidence that DLC1 protein, which predominantly associated with focal adhesions and localized in cytosol, dynamically shuttled between cytoplasm and nucleus. Treatment of cells with nuclear export blocker, Leptomycin B (LMB), retained DLC1 in the nucleus. To understand the nuclear entry of DLC1, we identified amino acids 600–700 of DLC1 as a novel region that is important for its nuclear localization. The tumor suppressive activity of nuclear DLC1 was directly assessed by employing a nuclear localization signal (NLS) fusion variant of DLC1 (NLS-DLC1) with preferential nuclear localization. In SMMC-7721 HCC cells, expression of NLS-DLC1 failed to suppress colony formation and actin stress fiber formation in vitro. The abrogated tumor suppressive activity of nuclear DLC1 was demonstrated for the first time in vivo by subcutaneously injecting p53(−/−) RasV12 hepatoblasts with stable NLS-DLC1 expression in nude mice. The injected hepatoblasts with NLS-DLC1 expression effectively formed tumors when compared with the non-nuclear targeted DLC1. CONCLUSIONS/SIGNIFICANCE: Our study identified a novel region responsible for the nuclear entry of DLC1 and demonstrated the functional difference of DLC1 in different cellular compartments both in vitro and in vivo.
format Online
Article
Text
id pubmed-3180446
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31804462011-09-30 Nuclear-Targeted Deleted in Liver Cancer 1 (DLC1) Is Less Efficient in Exerting Its Tumor Suppressive Activity Both In Vitro and In Vivo Chan, Lo-Kong Ko, Frankie Chi Fat Sze, Karen Man-Fong Ng, Irene Oi-Lin Yam, Judy Wai Ping PLoS One Research Article BACKGROUND: Deleted in liver cancer 1 (DLC1) serves as an important RhoGTPase activating protein (RhoGAP) protein that terminates active RhoA signaling in human cancers. Increasing evidence has demonstrated that the tumor suppressive activity of DLC1 depends not only on RhoGAP activity, but also relies on proper focal adhesion localization through its interaction with tensin family proteins. Recently, there are reports showing that DLC1 can also be found in the nucleus; however, the existence and the relative tumor suppressive activity of nuclear DLC1 have never been clearly addressed. METHODOLOGY AND PRINCIPAL FINDINGS: We herein provide new evidence that DLC1 protein, which predominantly associated with focal adhesions and localized in cytosol, dynamically shuttled between cytoplasm and nucleus. Treatment of cells with nuclear export blocker, Leptomycin B (LMB), retained DLC1 in the nucleus. To understand the nuclear entry of DLC1, we identified amino acids 600–700 of DLC1 as a novel region that is important for its nuclear localization. The tumor suppressive activity of nuclear DLC1 was directly assessed by employing a nuclear localization signal (NLS) fusion variant of DLC1 (NLS-DLC1) with preferential nuclear localization. In SMMC-7721 HCC cells, expression of NLS-DLC1 failed to suppress colony formation and actin stress fiber formation in vitro. The abrogated tumor suppressive activity of nuclear DLC1 was demonstrated for the first time in vivo by subcutaneously injecting p53(−/−) RasV12 hepatoblasts with stable NLS-DLC1 expression in nude mice. The injected hepatoblasts with NLS-DLC1 expression effectively formed tumors when compared with the non-nuclear targeted DLC1. CONCLUSIONS/SIGNIFICANCE: Our study identified a novel region responsible for the nuclear entry of DLC1 and demonstrated the functional difference of DLC1 in different cellular compartments both in vitro and in vivo. Public Library of Science 2011-09-26 /pmc/articles/PMC3180446/ /pubmed/21966542 http://dx.doi.org/10.1371/journal.pone.0025547 Text en Chan et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Chan, Lo-Kong
Ko, Frankie Chi Fat
Sze, Karen Man-Fong
Ng, Irene Oi-Lin
Yam, Judy Wai Ping
Nuclear-Targeted Deleted in Liver Cancer 1 (DLC1) Is Less Efficient in Exerting Its Tumor Suppressive Activity Both In Vitro and In Vivo
title Nuclear-Targeted Deleted in Liver Cancer 1 (DLC1) Is Less Efficient in Exerting Its Tumor Suppressive Activity Both In Vitro and In Vivo
title_full Nuclear-Targeted Deleted in Liver Cancer 1 (DLC1) Is Less Efficient in Exerting Its Tumor Suppressive Activity Both In Vitro and In Vivo
title_fullStr Nuclear-Targeted Deleted in Liver Cancer 1 (DLC1) Is Less Efficient in Exerting Its Tumor Suppressive Activity Both In Vitro and In Vivo
title_full_unstemmed Nuclear-Targeted Deleted in Liver Cancer 1 (DLC1) Is Less Efficient in Exerting Its Tumor Suppressive Activity Both In Vitro and In Vivo
title_short Nuclear-Targeted Deleted in Liver Cancer 1 (DLC1) Is Less Efficient in Exerting Its Tumor Suppressive Activity Both In Vitro and In Vivo
title_sort nuclear-targeted deleted in liver cancer 1 (dlc1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180446/
https://www.ncbi.nlm.nih.gov/pubmed/21966542
http://dx.doi.org/10.1371/journal.pone.0025547
work_keys_str_mv AT chanlokong nucleartargeteddeletedinlivercancer1dlc1islessefficientinexertingitstumorsuppressiveactivitybothinvitroandinvivo
AT kofrankiechifat nucleartargeteddeletedinlivercancer1dlc1islessefficientinexertingitstumorsuppressiveactivitybothinvitroandinvivo
AT szekarenmanfong nucleartargeteddeletedinlivercancer1dlc1islessefficientinexertingitstumorsuppressiveactivitybothinvitroandinvivo
AT ngireneoilin nucleartargeteddeletedinlivercancer1dlc1islessefficientinexertingitstumorsuppressiveactivitybothinvitroandinvivo
AT yamjudywaiping nucleartargeteddeletedinlivercancer1dlc1islessefficientinexertingitstumorsuppressiveactivitybothinvitroandinvivo